Ambrilia Biopharma Inc.
TSX : AMB

Ambrilia Biopharma Inc.

January 30, 2007 17:03 ET

Ambrilia Announces Election of New Chairman and Appointment of New Member to its Board of Directors

Attention Business/Financial/Health Editors

MONTREAL, QUEBEC--(CCNMatthews - Jan. 30, 2007) - Ambrilia Biopharma Inc.(TSX:AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today that Mr. Stephen G. Sudovar, a highly accomplished pharmaceutical executive and current member of Ambrilia's Board of Directors, has been unanimously elected Chairman of the Board. In connection with this appointment, Dr. Max Link resigned as director and Chairman of the Board. Dr. Link served as a director of Ambrilia since 1999 and as Chairman of the Board since May 2005. Ambrilia also announced the appointment of Mr. Frederic Porte, President of Medipress Management Inc., as a new director of the Company. Dr. Bernard Coupal, President of T2/C2 and a director of Ambrilia since 1999, resigned.

"I am pleased to report that Stephen Sudovar was voted unanimously to the Chairman's position and I believe that his track record in driving business growth in the global life sciences industry will be an asset to the Company," said Hans J. Mader, President and Chief Executive Officer of Ambrilia. "This nomination is in line with Ambrilia's corporate strategy to increase its presence in the U.S. biotech market," he added. "I would also like to take this opportunity to express my utmost gratitude to Dr. Max Link for his sound guidance throughout the years as well as his dedication in making Ambrilia a growing Company. While the members of the Board and I understand his decision considering his increasing workload as an active professional director within numerous U.S. companies, we are still sorry to see him leave," he continued. "Equally, I would like to thank Dr. Coupal, a prominent figure in the Quebec biotechnology community, for his committed support to the Company's development since 1999," he concluded.

"Ambrilia is building solid fundamentals and I believe is poised for future growth having significant potential opportunities in its product portfolio," said Stephen G. Sudovar, Chairman of Ambrilia's Board. "I am delighted to be able to further contribute to its development," he added. "Finally, I would like to welcome Frederic Porte to the Board and look forward to working with him in supporting both the financial and strategic plan of the Company," he concluded.

STEPHEN G. SUDOVAR

Mr. Sudovar is currently CEO of SGS Associates, a health care consulting firm. Prior to this position, he was President and Chief Executive Officer of Elusys Therapeutics, a U.S. Biotechnology Company. Mr. Sudovar's career spans thirty years of accomplishments in driving business growth in the health care products and services industry. He held senior management and related cross functional positions at Hoffmann La Roche, including President of its Roche Laboratories division from 1988 to 1999. During his tenure at Roche Labs, he more than tripled U.S. revenues, consistently increased divisional profit contribution, increased the company's U.S. market share, prepared the organization for the launch of many large products as well as integrated the Syntex and Boehringer Mannheim U.S. operations into Roche. As a member of the Roche Board of Directors and Executive Committee and the Chairman of the Business Operating Committee, he was also responsible for the U.S. related therapeutic area planning for drug discovery and portfolio management for drug development. During his tenure with Roche, he gained significant global experience as an expatriate in Europe. Mr. Sudovar also headed two successful start-up companies, Pracon Incorporated and Elusys Therapeutics. Mr. Sudovar is a member of the Board of Nabi Pharmaceuticals and Aastrom Biosciences. He was also Chairman of the National Pharmaceutical Council (NPC) and of the Marketing Section of the Pharmaceutical Research and Manufacturing Association (PhRMA). He holds a B.S. in Marketing from St Peter's College and an MBA from Fairleigh Dickinson University. He is an Adjunct Professor of Management at Montclair State University.

FREDERIC PORTE

Mr. Frederic Porte is a seasoned entrepreneur and businessman with more than 25 years of experience in the life sciences industry. During his career, Mr. Porte has founded 3 successful companies. He is currently the President and Founder of Medipress Management Inc., a firm offering financial and strategic services to healthcare and venture capital organizations for the evaluation of M&A and strategic alliances. Prior to that, he founded in 1987 Clinidata, a software and communication company developed in association with Royal Bank Capital Corporation and specialized in healthcare applications. Clinidata developed effective and sophisticated technologies supported by multinational corporations such as Merck, Pfizer, J&J, Schering Plough and Smith Kline Beecham, combined with strategic alliances with managed care organizations and professional associations. The company was acquired in 1994 by the pharmaceutical company Hoechst Marion Roussel. In 1980, he created and managed L'Actualite Medicale, a leading Canadian medical publishing company which was later acquired by MacLean Hunter. Mr. Porte has a degree in Business Administration and Finance from l'Ecole Superieure de Commerce de Lyon (France) and a D.E.A. in Sciences of Information from the University of Sorbonne (France). Mr. Porte is a director and member of the audit Committees of Labopharm and Bioaxone Therapeutique Inc. He is also a director and a member of the investment Committee of Angelus Investment Corporation.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc.(TSX:AMB) is a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases. Ambrilia's product portfolio includes an anti-cancer therapeutic peptide (PCK3145), a Tumor Vasculature Targeting (TVT) technology platform, two improved formulations of existing drugs (Octreotide and Goserelin) developed with a patented delivery system technology, promising anti-HIV treatments (PPL-100, recently licensed to Merck & Co., Inc., and a HIV Integrase Inhibitor Program) as well as other antivirals and immunomodulators. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site: www.ambrilia.com

Ambrilia's forward-looking statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward-looking statements.

Contact Information